Results of a Phase Ib Trial of Combination Immunotherapy With a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients

According to researchers, the GP2 + GM-CSF vaccine is safe and stimulates an immunologic response when administered concurrently with trastuzumab patients with breast cancer. An ongoing phase II trial is evaluating the efficacy of combining a CD8 T-cell-eliciting vaccine with trastuzumab in HER2-positive breast cancer patients.

 Ann Surg Oncol